Literature DB >> 18802328

Elevated osteoprotegerin levels predict cardiovascular events in new hemodialysis patients.

Ryosuke Nishiura1, Shouichi Fujimoto, Yuji Sato, Kazuhiro Yamada, Shuichi Hisanaga, Seiichiro Hara, Hiroyuki Nakao, Kazuo Kitamura.   

Abstract

BACKGROUND: Patients on hemodialysis (HD) frequently experience cardiovascular events associated with vascular calcification. We investigated the involvement of osteoprotegerin (OPG), an inhibitor of vascular calcification, in the incidence of cardiovascular events and mortality among new HD patients.
METHODS: We conducted a prospective cohort study of the association of serum OPG levels with morbidity and mortality in subjects who became new HD patients between June 2000 and May 2006.
RESULTS: A total of 99 patients (age 58.9 +/- 14.6 years, 65 male, 34 female) were prospectively followed up for 41.5 +/- 20.2 months. During this period, 27 patients developed cardiovascular events and 12 died of causes related to cardiovascular disease. When divided into 2 groups according to OPG levels, the high OPG group showed a higher prevalence of cardiovascular morbidity and mortality compared with the low OPG group. Cox's proportional hazards analysis associated the new onset of cardiovascular events with the high OPG group (HR 2.88, 95% CI 1.09-7.62, p = 0.033). Furthermore, the high OPG group at the start of HD was significantly associated with older age, male gender and a high aortic calcification index.
CONCLUSIONS: Elevated levels of serum OPG in new HD patients may predict subsequent cardiovascular events. 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18802328     DOI: 10.1159/000157629

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  10 in total

Review 1.  Vascular calcification in chronic kidney disease: Pathogenesis and clinical implication.

Authors:  Sinee Disthabanchong
Journal:  World J Nephrol       Date:  2012-04-06

2.  Plasma osteoprotegerin, arterial stiffness, and mortality in normoalbuminemic Japanese hemodialysis patients.

Authors:  A Nakashima; J J Carrero; A R Qureshi; T Hirai; N Takasugi; T Ueno; Y Taniguchi; B Lindholm; N Yorioka
Journal:  Osteoporos Int       Date:  2010-09-02       Impact factor: 4.507

3.  Serum anti-DIDO1, anti-CPSF2, and anti-FOXJ2 antibodies as predictive risk markers for acute ischemic stroke.

Authors:  Takaki Hiwasa; Hao Wang; Ken-Ichiro Goto; Seiichiro Mine; Toshio Machida; Eiichi Kobayashi; Yoichi Yoshida; Akihiko Adachi; Tomoo Matsutani; Mizuki Sata; Kazumasa Yamagishi; Hiroyasu Iso; Norie Sawada; Shoichiro Tsugane; Mitoshi Kunimatsu; Ikuo Kamitsukasa; Masahiro Mori; Kazuo Sugimoto; Akiyuki Uzawa; Mayumi Muto; Satoshi Kuwabara; Yoshio Kobayashi; Mikiko Ohno; Eiichiro Nishi; Akiko Hattori; Masashi Yamamoto; Yoshiro Maezawa; Kazuki Kobayashi; Ryoichi Ishibashi; Minoru Takemoto; Koutaro Yokote; Hirotaka Takizawa; Takashi Kishimoto; Kazuyuki Matsushita; Sohei Kobayashi; Fumio Nomura; Takahiro Arasawa; Akiko Kagaya; Tetsuro Maruyama; Hisahiro Matsubara; Minako Tomiita; Shinsaku Hamanaka; Yushi Imai; Tomoo Nakagawa; Naoya Kato; Jiro Terada; Takuma Matsumura; Yusuke Katsumata; Akira Naito; Nobuhiro Tanabe; Seiichiro Sakao; Koichiro Tatsumi; Masaaki Ito; Fumiaki Shiratori; Makoto Sumazaki; Satoshi Yajima; Hideaki Shimada; Mikako Shirouzu; Shigeyuki Yokoyama; Takashi Kudo; Hirofumi Doi; Katsuro Iwase; Hiromi Ashino; Shu-Yang Li; Masaaki Kubota; Go Tomiyoshi; Natsuko Shinmen; Rika Nakamura; Hideyuki Kuroda; Yasuo Iwadate
Journal:  BMC Med       Date:  2021-06-09       Impact factor: 8.775

4.  Relationship between serum osteoprotegerin and vascular calcifications in hemodialysis patients.

Authors:  Tarek Z El Baz; Osama A Khamis; Amal El-Shehaby; Hussein Chahine; Ahmad Alaa Al-Din Ahmed; Mostafa A Alsawasany
Journal:  Egypt Heart J       Date:  2017-03-09

5.  Association between serum anti‑ASXL2 antibody levels and acute ischemic stroke, acute myocardial infarction, diabetes mellitus, chronic kidney disease and digestive organ cancer, and their possible association with atherosclerosis and hypertension.

Authors:  Shu-Yang Li; Yoichi Yoshida; Eiichi Kobayashi; Akihiko Adachi; Seiichiro Hirono; Tomoo Matsutani; Seiichiro Mine; Toshio Machida; Mikiko Ohno; Eiichiro Nishi; Yoshiro Maezawa; Minoru Takemoto; Koutaro Yokote; Kenichiro Kitamura; Makoto Sumazaki; Masaaki Ito; Hideaki Shimada; Hirotaka Takizawa; Koichi Kashiwado; Go Tomiyoshi; Natsuko Shinmen; Rika Nakamura; Hideyuki Kuroda; Xiao-Meng Zhang; Hao Wang; Kenichiro Goto; Yasuo Iwadate; Takaki Hiwasa
Journal:  Int J Mol Med       Date:  2020-07-29       Impact factor: 4.101

6.  Serum anti-AP3D1 antibodies are risk factors for acute ischemic stroke related with atherosclerosis.

Authors:  Shu-Yang Li; Yoichi Yoshida; Eiichi Kobayashi; Masaaki Kubota; Tomoo Matsutani; Seiichiro Mine; Toshio Machida; Yoshiro Maezawa; Minoru Takemoto; Koutaro Yokote; Yoshio Kobayashi; Hirotaka Takizawa; Mizuki Sata; Kazumasa Yamagishi; Hiroyasu Iso; Norie Sawada; Shoichiro Tsugane; Sohei Kobayashi; Kazuyuki Matsushita; Fumio Nomura; Hisahiro Matsubara; Makoto Sumazaki; Masaaki Ito; Satoshi Yajima; Hideaki Shimada; Katsuro Iwase; Hiromi Ashino; Hao Wang; Kenichiro Goto; Go Tomiyoshi; Natsuko Shinmen; Rika Nakamura; Hideyuki Kuroda; Yasuo Iwadate; Takaki Hiwasa
Journal:  Sci Rep       Date:  2021-06-29       Impact factor: 4.379

7.  Serum osteoprotegerin is associated with vascular stiffness and the onset of new cardiovascular events in hemodialysis patients.

Authors:  Jung Eun Lee; Hyung Jong Kim; Sung Jin Moon; Ji Sun Nam; Jwa-Kyung Kim; Seung Kyu Kim; Gi Young Yun; Sung Kyu Ha; Hyeong Cheon Park
Journal:  Korean J Intern Med       Date:  2013-10-29       Impact factor: 2.884

8.  Serum osteoprotegerin in prevalent hemodialysis patients: associations with mortality, atherosclerosis and cardiac function.

Authors:  Sílvia Collado; Elisabeth Coll; Carlos Nicolau; Manel Azqueta; Mercedes Pons; Josep M Cruzado; Bernat de la Torre; Ramón Deulofeu; Sergi Mojal; Julio Pascual; Aleix Cases
Journal:  BMC Nephrol       Date:  2017-09-07       Impact factor: 2.388

9.  Osteoprotegerin and Cardiovascular Events in High-Risk Populations: Meta-Analysis of 19 Prospective Studies Involving 27 450 Participants.

Authors:  Lena Tschiderer; Gerhard Klingenschmid; Rajini Nagrani; Johann Willeit; Jari A Laukkanen; Georg Schett; Stefan Kiechl; Peter Willeit
Journal:  J Am Heart Assoc       Date:  2018-08-21       Impact factor: 5.501

10.  Association of sclerostin with cardiovascular events and mortality in dialysis patients.

Authors:  Yun Zou; Min Yang; Jiao Wang; Li Cui; Zhenxing Jiang; Jiule Ding; Min Li; Hua Zhou
Journal:  Ren Fail       Date:  2020-11       Impact factor: 2.606

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.